We did not observe any correlation between sensitivity to Chk1 inhibitor and the presence of a Myc-gene expression signature, suggesting that the high sensitivity to this class of compounds described in mouse models of Myc-driven lymphomas [29] might depend more on the deregulated cell cycle and DNA damage repair mechanisms rather than on the deregulation of Myc itself. The gene discussed is MYC; the disease is lymphoma.